Valuation: Satellos Bioscience Inc.

Market Cap 202M 177M 164M 151M 284M 19.48B 289M 1.96B 766M 9.53B 758M 742M 32.93B P/E 2026 *
-5.53x
P/E 2027 * -5.9x
Enterprise Value 108M 94.83M 88.04M 80.9M 152M 10.44B 155M 1.05B 410M 5.11B 406M 398M 17.65B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
93.52%
Yield 2026 *
-
Yield 2027 * -
1 day+14.71%
1 week+12.44%
Current month+28.05%
1 month+70.41%
3 months+31.76%
6 months+6.31%
Current year+72.35%
1 week 11.39
Extreme 11.39
13.65
1 month 7.76
Extreme 7.76
14.15
Current year 7.67
Extreme 7.67
18.98
1 year 6.36
Extreme 6.36
18.98
3 years 3.48
Extreme 3.48
18.98
5 years 2.58
Extreme 2.58
22.8
10 years 2.58
Extreme 2.58
22.8
Manager TitleAgeSince
Chief Executive Officer 70 01/03/2018
Chief Tech/Sci/R&D Officer - 01/05/2018
Director of Finance/CFO - 01/09/2023
Director TitleAgeSince
Chairman 59 01/07/2018
Director/Board Member 50 01/03/2018
Director/Board Member 70 01/07/2012
Date Insider Type Main position Quantity % Market Cap.
18/6/26 Buy

Director

15,000 0.0720%
7/4/26 Option

Founder

108,630 0.7027%
7/4/26 Buy

Director

4,500 0.0291%
Change 5-day change 1-year change 3-year change Capi.($)
+14.71%+12.44%+92.80%+158.52% 202M
-0.43%-4.26%+52.09%+85.69% 55.27B
+3.98%+4.93%+61.15%+64.38% 54.15B
-1.82%-2.89%+3.61%+405.88% 23.11B
-0.54%-0.17%-17.60%-15.43% 23.22B
+0.77%-0.46%+36.14%-3.48% 20.33B
-1.61%-0.71%+29.49%-30.33% 17.91B
+0.39%-0.57%+38.53%+551.00% 15.76B
+0.43%-10.61%+175.63%+299.61% 15B
-2.03%-1.03%+23.63%+179.23% 13.82B
Average +1.36%-0.24%+49.55%+169.51% 23.88B
Weighted average by Cap. +0.42%-1.04%+44.87%+135.35%

Financials

2026 *2027 *
Net sales - -
Net income -48.32M -42.34M -39.31M -36.12M -68.06M -4.66B -69.06M -468M -183M -2.28B -181M -177M -7.88B -56.57M -49.56M -46.01M -42.28M -79.67M -5.46B -80.85M -548M -215M -2.67B -212M -208M -9.23B
Net Debt -93.65M -82.06M -76.18M -70M -132M -9.04B -134M -907M -355M -4.42B -352M -344M -15.28B -111M -97.56M -90.57M -83.23M -157M -10.74B -159M -1.08B -422M -5.26B -418M -409M -18.16B
Logo Satellos Bioscience Inc.
Satellos Bioscience Inc. is a Canada-based clinical-stage drug development company. The Company is focused on restoring natural muscle repair and regeneration in degenerative muscle diseases. Through its research, the Company has developed SAT-3247, a first-of-its-kind, orally administered small molecule drug designed to address deficits in muscle repair and regeneration. SAT-3247 targets AAK1, a key protein that has identified as capable of replacing the signal normally provided by dystrophin in muscle stem cells to effect repair and regeneration. It is also leveraging its proprietary discovery platform MyoReGenX to identify additional muscle diseases or injury conditions where restoring muscle repair and regeneration may have therapeutic benefit and represent future clinical development opportunities. With this platform, the Company is building a pipeline of therapeutics to correct muscle stem cell polarity and promote the body’s innate muscle repair and regeneration process.
Employees
20
Date Price Change Volume
22/07/26 CAD 13.65 +14.71% 21,994
21/07/26 CAD 11.90 +1.54% 24,820
20/07/26 CAD 11.72 -4.64% 37,672
17/07/26 CAD 12.29 +1.07% 35,122
16/07/26 CAD 12.16 +0.16% 83,678
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
13.65CAD
Average target price
17.67CAD
Spread / Average Target
+29.43%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. MSCL Stock